Does PainReform Ltd (PRFX) Have What it Takes to be in Your Portfolio Friday?

PainReform Ltd (PRFX) is around the top of the Drug Manufacturers - Specialty & Generic industry according to InvestorsObserver. PRFX received an overall rating of 62, which means that it scores higher than 62 percent of all stocks. PainReform Ltd also achieved a score of 90 in the Drug Manufacturers - Specialty & Generic industry, putting it above 90 percent of Drug Manufacturers - Specialty & Generic stocks. Drug Manufacturers - Specialty & Generic is ranked 134 out of the 148 industries.

PRFX has an Overall Score of 62. Find out what this means to you and get the rest of the rankings on PRFX!

See Full PRFX Report

What do These Ratings Mean?

Finding the best stocks can be tricky. It isn’t easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObserver’s tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector. This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

What's Happening With PainReform Ltd Stock Today?

PainReform Ltd (PRFX) stock is down -1.2% while the S&P 500 has risen 0.93% as of 10:25 AM on Friday, Jul 28. PRFX is down -$0.08 from the previous closing price of $6.66 on volume of 42,789 shares. Over the past year the S&P 500 has gained 12.45% while PRFX has risen 1.23%. PRFX lost -$8.77 per share the over the last 12 months. Click Here to get the full Stock Report for PainReform Ltd stock.